Search
Influenza A virus A/Massachusetts/18/2022 (H3N2) recombinant hemagglutinin antigen
go.drugbank.com/drugs/DB19322ApprovedWithdrawnRecombinant influenza vaccines are produced by synthesizing recombinant influenza hemagglutinin antigen in a laboratory and do not require the use of candidate viruses or egg-based manufacturing processes … These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen
Influenza A virus A/Thailand/8/2022 IVR-237 (H3N2) antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB19323ApprovedWithdrawnRecombinant influenza vaccines are produced by synthesizing recombinant influenza hemagglutinin antigen in a laboratory and do not require the use of candidate viruses or egg-based manufacturing processes … These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen
Influenza A virus A/Thailand/8/2022 IVR-237 antigen (UV, formaldehyde inactivated)
go.drugbank.com/drugs/DB19324ApprovedWithdrawnRecombinant influenza vaccines are produced by synthesizing recombinant influenza hemagglutinin antigen in a laboratory and do not require the use of candidate viruses or egg-based manufacturing processes … These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen
Influenza A Virus A/Thailand/8/2022 IVR-237 (H3N2) whole
go.drugbank.com/drugs/DB19413ApprovedRecombinant influenza vaccines are produced by synthesizing recombinant influenza hemagglutinin antigen in a laboratory and do not require the use of candidate viruses or egg-based manufacturing processes … These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen
Denileukin diftitox
go.drugbank.com/drugs/DB00004ApprovedInvestigational[A264349, L51254] Denileukin diftitox was originally approved by the FDA in 1999 for the treatment of cutaneous T-cell lymphoma (CTCL),[A264339, L51264] making it the first fusion protein cytotoxin … on August 8, 2024.
Synonyms: N-MET-187-HIS-388-ALA-1-388-TOXIN (CORYNEBACTERIUM DIPHTHERIAE C7) WITH 1-133-INTERLEUKIN 2, N-L-METHIONYL-387-L-HISTIDINE-388-L-ALANINE-1-388-TOXIN (CORYNEBACTERIUM DIPHTHERIAE STRAIN C7) (388->2') PROTEIN WITH 2-133-INTERLEUKIN 2 (HUMAN CLONE PTIL2-21A)Fentanyl
go.drugbank.com/drugs/DB00813ApprovedIllicitInvestigationalVet approvedFentanyl, a potent opioid agonist, was developed in the 1950s to fill a need for strong and rapid analgesia. … [A179542] Because of these characteristics, fentanyl is commonly used to treat chronic cancer pain or in anesthesia.
Synonyms: N-phenethyl-4-(N-propionylanilino)piperidine, N-(1-phenethyl-4-piperidinyl)-N-phenylpropionamideCategories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeMMDA
go.drugbank.com/drugs/DB01442ExperimentalIllicitMMDA bears resemblance to the psychopharmacologically active essential oils elemicin and myristicin found in nutmeg.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeCefapirin
go.drugbank.com/drugs/DB01139ApprovedVet approvedCefapirin (INN, also spelled cephapirin), commonly marketed under the trade name Cefadyl, is a first-generation cephalosporin antibiotic that is available in injectable formulations. Production for use in humans has been discontinued in ...
Cinnamaldehyde
go.drugbank.com/drugs/DB14184ApprovedSensitivity to cinnamaldehyde may be identified with a clinical patch test.
Glycyrrhiza glabra
go.drugbank.com/drugs/DB14312ApprovedInvestigationalWithdrawnIt is not an approved drug.
Categories: Non-Standardized Food Allergenic Extract, Non-Standardized Plant Allergenic Extract